20.08.2025 • Topics

M&A in the Chemical Industry

Navigating Uncertainty While Unlocking Strategic Opportunities

Wolfgang Kazmierowski and Christian Dehm, DC Advisory

M&A activities in the chemical industry are on the rise again, and companies with a clear strategy and consistent action will be particularly successful in the future.
© gothong_1984 - stock.adobe.com

Mergers and acquisitions (M&A) are both a driver and a reflection of consolidation in the chemical industry. They allow companies to adapt to a challenging environment, leverage synergies and strengthen their market position. Consolidation in the industry will continue, particularly in segments with persistent margin pressure, but also where investors can benefit from long-term trends such as sustainability and innovation.

The global chemical M&A market is facing a period of significant complexity. Investor confidence has been unsettled by a mix of geopolitical tensions, inflation, and regulatory shifts, creating a cautious environment for dealmaking. While general market sentiment remains mixed, we believe both investors and sellers are active in principle. 

Financial sponsors with dry powder are scanning the market for the right opportunities, while several large chemical groups are preparing to divest non-core assets as part of broader portfolio restructuring.

Continue with login

No account yet?

Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.

Register

Company

Logo:

DCAT - Drug, Chemical & Associated Technologies Association

One Union St., Suite 208
Robbinsville
US

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read